10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $151.04 million versus the consensus estimate of $146.64 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.